Loading page content…
Loading page content…
Loading contract search results…
Loading contract details…
| Source: | Find a Tender Service (FTS) |
| Notice Type: | Tender notice |
| Buyer: | NHS England |
| Main Category: | Goods |
| Procurement Method: | Open procedure |
| Tender Status: | Closed |
| Estimated Value (ex. VAT): | £1,520,432,295 |
| Estimated Value (inc. VAT): | £1,824,518,754 |
| Release Date: | 19 June 2025 |
| Application Deadline: | 14 July 2025 |
| Procurement ID (OCID): | ocds-h6vhtk-055064 |
| Notice Reference: | 033860-2025 |
All 4 notices for this procurement, oldest first.
NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025
NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025
NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025
NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025
View Original Notice
Access the full notice on the official portal
Awarded to (15 suppliers)
| Award status: | Active |
| Call-off method: | Direct call-off (no competition) |
Provision of Licensed Medical Retinal Vascular Anti Veg-F and Intravitreal Corticosteroid medicines used in medical retinal vascular services for the NHS in England. To include but not limited to aflibercept, bevacizumab, brolucizumab, intravitreal dexamethasone, intravitreal fluocinolone, faricimab and ranibizumab used in the treatment of; • neovascular (wet) age-related macular degeneration (AMD) • visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) • proliferative diabetic retinopathy (PDR) • visual impairment due to diabetic macular oedema (DME) • visual impairment due to diabetic macular oedema (DME) who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy • vision impairment associated with chronic diabetic macular oedema, (DME) • visual impairment due to myopic choroidal neovascularisation (myopic CNV) • retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 2+ or 3+) or AP-ROP (aggressive posterior ROP) disease • inflammation of the posterior segment of the eye presenting as non-infectious uveitis • prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye
CM/PHS/25/5728/01 - National Framework for Medical Retinal Vascular Treatments: 7NAT (National)
CM/PHS/25/5728/02 - Regional Framework for Medical Retinal Vascular Treatments aflibercept 2mg
Document pack· 1 file
Published contracts in the last 12 months
2,046
total contracts
£179666.3m
total value
£251,986,446
average contract size
Typical categories
Pipeline status
Not addedImports the contract into your BidWriter pipeline · Qualify before you commit to bid
Application Deadline
14 July 2025
Closed
Estimated Value
£1,520,432,295
Need help writing this bid?
Our specialists write winning tender responses. Free consultation, no obligation.
Book a free consultation →